title: The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
abstract: Primary nodal marginal zone lymphoma (NMZL) is a rare disease. There is no current consensus on how to treat it. The bendamustine plus rituximab (BR) regimen is effective for the treatment of follicular and other indolent lymphomas, but its efficacy in NMZL is not known. We analyzed the outcome of 14 patients diagnosed with NMZL (median age 67 years) who were treated with 375 mg/m2of rituximab on day 1 and 90 mg/m2of bendamustine on days 1 and 2. The overall and complete response rates were 93% and 71%, respectively. Major toxicity (grade 3/4 neutropenia) occurred in 5% of treatment courses. After a median follow-up of 22 months (range: 18-55), the overall survival and the free survival rates were 100% and 93%, respectively. None of the patients showing a complete or partial response developed secondary myelodysplastic syndrome/acute myeloid leukemia. Bendamustine plus rituximab was found to be an active and well-tolerated regimen leading to the rapid control of disease.
authors.affiliation: Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Kamel
authors.initials: K
authors.lastname: Laribi
authors.affiliation: Department of Hematology, Institut de Cancéro-Hématologie, CHRU Brest, Brest, France.
authors.forename: Adrien
authors.initials: A
authors.lastname: Tempescul
authors.affiliation: Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Habib
authors.initials: H
authors.lastname: Ghnaya
authors.affiliation: Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Denizon
authors.affiliation: Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Besançon
authors.affiliation: Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Andreea
authors.initials: A
authors.lastname: Anghel
authors.affiliation: Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Farhi
authors.affiliation: Clinical Research Center, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Truong
authors.affiliation: Laboratory of Biology and Hematology, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Lemaire
authors.affiliation: Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France.|Laboratoire d'Hématologie, Centre de Biologie et Pathologie, CHRU de Lille, Lille, France.|INSERM UMR 1172, IRCL, Lille, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Poulain
authors.affiliation: Department of Pharmacy, Centre Hospitalier du Mans, Le Mans, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Bolle
authors.affiliation: Department of Hematology, Institut de Cancéro-Hématologie, CHRU Brest, Brest, France.
authors.forename: Jean Christophe
authors.initials: JC
authors.lastname: Ianotto
authors.affiliation: Department of Medicine, Pôle Santé Sud, Le Mans, France.
authors.forename: Alix
authors.initials: A
authors.lastname: Baugier de Materre
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D000069283:Rituximab / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride
keywords: active; bendamustine; nodal marginal zone lymphoma; rituximab; well tolerated